首页> 外文OA文献 >Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
【2h】

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.

机译:顺序DTIC和Fotemustine化疗后,人白细胞DNA中O6-甲基脱氧鸟苷的形成和丢失。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is increasing evidence to indicate that O6-methyldeoxyguanosine (O6-MedG) formation in DNA is a critical cytotoxic event following exposure to certain anti-tumour alkylating agents and that the DNA repair protein O6-alkylguanine-DNA alkyltransferase (ATase) can confer resistance to these agents. We recently demonstrated a wide inter-individual variation in the depletion and subsequent regeneration of ATase in human peripheral blood lymphocytes following sequential DTIC (400 mg m-2) and fotemustine (100 mg m-2) treatment, with the nadir ATase activity occurring approximately 4 h after DTIC administration. We have now measured the formation and loss of O6-methyldeoxyguanosine (O6-MedG) in the DNA of peripheral leucocytes of eight patients receiving this treatment regimen. O6-MedG could be detected within 1 h and maximal levels occurred approximately 3-5 h after DTIC administration. Following the first treatment cycle, considerable inter-individual variation was observed in the peak O6-MedG levels, with values ranging from 0.71 to 14.3 mumol of O6-MedG per mol of dG (6.41 +/- 5.53, mean +/- s.d.). Inter- and intra-individual variation in the extent of O6-MedG formation was also seen in patients receiving additional treatment cycles. This may be a consequence of inter-patient differences in the capacity for metabolism of DTIC to release a methylating intermediate and could be one of the determinants of clinical response. Both the pretreatment ATase levels and the extent of ATase depletion were inversely correlated with the amount of O6-MedG formed in leucocyte DNA when expressed either as peak levels (r = -0.59 and -0.75 respectively) or as the area under the concentration-time curve (r = -0.72 and -0.73 respectively). One complete and one partial clinical response were seen, and these occurred in the two patients with the highest O6-MedG levels in the peripheral leucocyte DNA, although the true significance of this observation has yet to be established.
机译:越来越多的证据表明,暴露于某些抗肿瘤烷基化剂后,DNA中的O6-甲基脱氧鸟苷(O6-MedG)形成是关键的细胞毒性事件,DNA修复蛋白O6-烷基鸟嘌呤-DNA烷基转移酶(ATase)可以赋予抗药性这些代理商。我们最近证明,在连续DTIC(400 mg m-2)和Fotemustine(100 mg m-2)处理后,人类外周血淋巴细胞中ATase的耗竭和随后的再生存在广泛的个体差异,最低点的ATase活性大约发生DTIC给药后4小时。现在,我们已经测量了八名接受这种治疗方案的患者外周血白细胞的DNA中O6-甲基脱氧鸟苷(O6-MedG)的形成和丢失。 DTIC给药后约1到3个小时内即可检测到O6-MedG,最高水平。在第一个治疗周期后,观察到O6-MedG峰值水平之间存在很大的个体差异,其值范围为每摩尔dG 0.71至14.3μmolO6-MedG(6.41 +/- 5.53,平均值+/- sd) 。在接受额外治疗周期的患者中,O6-MedG形成程度的个体间和个体内差异也被观察到。这可能是由于患者之间DTIC代谢释放甲基化中间体的代谢能力不同而造成的,并且可能是临床反应的决定因素之一。当以峰值水平(分别为r = -0.59和-0.75)或浓缩时间下的面积表示时,预处理中的ATase水平和ATase耗竭程度均与白细胞DNA中形成的O6-MedG量呈负相关。曲线(分别为r = -0.72和-0.73)。观察到一种完全和部分的临床反应,这些反应发生在外周血白细胞DNA中O6-MedG水平最高的两名患者中,尽管这一观察的真正意义尚未确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号